Overview
- Adjusted EPS reached $1.86 on revenue of $7.9 billion, topping Wall Street forecasts of $1.81 and $7.7 billion.
- Flagship HIV therapy Biktarvy generated $4.0 billion in Q4 sales, ahead of analyst expectations of $3.8 billion.
- Yeztugo, the twice-yearly PrEP shot, delivered $96 million in Q4 and is guided to $800 million in 2026, a ramp analysts describe as achievable.
- For 2026, Gilead forecast adjusted EPS of $8.45 to $8.85 and product sales of $29.6 billion to $30.0 billion, trimmed by roughly 2% per management.
- CEO Daniel O’Day cited an MFN pricing agreement and ACA coverage uncertainty as headwinds, while market reactions ranged from a premarket decline to a gain of more than 5% in later trading.